戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 t to test the association between the use of alpha2 agonists and enhanced sedation.
2 inephrine (NE), clonidine (CLON, a selective alpha2-agonist) and phenylephrine (PE, a selective alpha
3 fect profiles when compared with traditional alpha2 agonists, and may thereby allow for more widespre
4                                      Besides alpha2-agonists, apical uptake was inhibited by verapami
5 ified into an exposed group, who received an alpha2 agonist as part of their sedation regimen, and an
6 ing the response to intravenous injection of alpha2-agonist before and after the infusion.
7 ttens received microinfusions (1 mul) of the alpha2 agonist clonidine (CLON; 1.32 nmol), and half rec
8 ,N-MePhe4, Gly-ol5]enkephalin (DAMGO) or the alpha2 agonist clonidine inhibited voltage-gated Ca2+ cu
9  of the alpha1-agonist phenylephrine and the alpha2-agonist clonidine.
10 ed evidence supporting the widespread use of alpha2 agonists (clonidine and dexmedetomidine) in pedia
11 cocaine CPP in the presence and absence of a alpha2-agonist (clonidine), beta-adrenergic receptor ant
12                                          The alpha2-agonist, clonidine, had a weak effect in LSI neur
13 eatment of HUVECs, but not neutrophils, with alpha2-agonists decreased transendothelial migration, wi
14                     The nonsubtype-selective alpha2 agonist dexmedetomidine completely blocked the co
15 both norepinephrine and the highly selective alpha2 agonist dexmedetomidine each reversed the VLPO de
16                                          The alpha2 Agonist Dexmedetomidine for REfractory Septic Sho
17                             Propofol and the alpha2 agonists dexmedetomidine and clonidine are used f
18  to investigate the role of the alpha2aAR in alpha2 agonist-evoked analgesia and adrenergic-opioid sy
19 ernal cesium and external barium, opioid and alpha2 agonists had no effect at potentials more negativ
20                                              Alpha2 agonists have been in clinical use for decades, p
21                             In recent years, alpha2 agonists have found wider application, particular
22                                              alpha2 agonists have similar potencies in stimulating Sr
23 nhibition of vas deferens contraction by the alpha2 agonist in alpha2A-AR knockout mice was only 42 +
24 phrine (an alpha1 agonist) and clonidine (an alpha2 agonist) in 10 healthy men during rhythmic handgr
25                                   To put the alpha2-agonists into clinical context, we will discuss t
26 ission at IPL and that brimonidine and other alpha2 agonists may protect RGCs under disease condition
27                  The mutation also decreased alpha2-agonist-mediated spinal analgesia and blocked the
28 y before naloxone with clonidine (20 microg; alpha2 agonist), MK-801 (3 microg; noncompetitive NMDA a
29                               Interestingly, alpha2-agonists prevented the TNF-alpha-mediated decreas
30                                Guanabenz, an alpha2-agonist, prolonged baseline expiration and potent
31                                              alpha2 Agonists, such as brimonidine, have been shown to
32 neuroprotection of retinal ganglion cells by alpha2 agonists, such as brimonidine, in animal models o
33            Compelling evidence suggests that alpha2 agonists, such as brimonidine, protect retinal ga
34                                          The alpha2 agonists that are currently employed in anesthesi
35 ther in murine nor in human neutrophils upon alpha2-agonist treatment.
36 he NE-induced inhibition was mimicked by the alpha2-agonist, UK14,304, but not by the alpha1- or beta
37 (P < 0.05) and sensitivity (P < 0.05) to the alpha2 agonist UK14304 was lower in protein-, but not in
38 ere was a shift toward lighter sedation with alpha2 agonist use.
39                                       Use of alpha2 agonists was associated with similar time adequat
40                    The hypotensive effect of alpha2 agonists was completely absent in alpha2A-deficie
41 eir hypnotic response to dexmedetomidine (an alpha2 agonist) was determined.
42                           Patients receiving alpha2 agonists were permitted to receive supplemental p
43 phrine (alpha1-agonist) and dexmedetomidine (alpha2-agonist) were assessed.
44 henylephrine (alpha1-agonist) and clonidine (alpha2-agonist) were assessed.
45 e (selective alpha1-agonist), and clonidine (alpha2-agonist) were determined in 10 young (aged 26+/-1
46 fter we will compare and contrast the use of alpha2-agonists with clinically available agents, and sp